GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (OTCPK:ORGS) » Definitions » Future 3-5Y EPS without NRI Growth Rate

ORGS (Orgenesis) Future 3-5Y EPS without NRI Growth Rate : N/A (As of May. 06, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Orgenesis Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Orgenesis's Future 3-5Y EPS without NRI Growth Rate is N/A.


Competitive Comparison of Orgenesis's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Orgenesis's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Orgenesis's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Orgenesis  (OTCPK:ORGS) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.


Orgenesis Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Orgenesis's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (OTCPK:ORGS) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Traded in Other Exchanges
N/A
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.
Executives
Jacob Safier 10 percent owner C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Elliot Maltz officer: Chief Financial Officer C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Efrat Assa Kunik officer: Chief Development Officer C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky director JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips director C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber officer: Chief Scientific Officer 17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin director 7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler director 4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan officer: CEO 20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles 10 percent owner AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger 10 percent owner DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret officer: See Remarks 48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda director 2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452